Inclusion Criteria:

1. Be at least 18 years of age

2. Have a confirmed diagnosis of MM

3. Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after
one prior treatment.

4. Have personally signed and dated a legally effective written informed consent form
prior to admission to the study.

5. Must be willing and able to understand and comply with the study requirements.

Exclusion Criteria:

1. Individuals who have taken any experimental drugs or participated in a clinical trial
within 30 days prior to screening.

2. Individuals with significant psychiatric illness or a clinically significant
acute/chronic uncontrolled medical condition that might affect their experience of
myeloma symptoms or their ability to describe them.